Zydus Lifesciences Limited has informed the Exchange regarding Outcome of Board Meeting held on May 19, 2026.
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.6 pts more than Nifty 100 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Lifesciences Limited's Board has approved a buyback of up to 95,65,217 equity shares (0.95% of paid-up capital) at INR 1,150 per share, for a total consideration not exceeding INR 1,100 crore. The buyback represents 5.16% and 3.84% of standalone and consolidated free reserves respectively as of March 31, 2026. The buyback will be conducted via the tender offer route on a proportionate basis, including for promoters. The record date for determining eligible shareholders is May 29, 2026. A Buyback Committee has been formed to oversee the process.
The buyback signals management confidence in the company's intrinsic value, offering shareholders an opportunity to exit at INR 1,150 per share. With promoters holding ~75% stake, minority shareholders can participate in the tender offer to realize value at the buyback price.